BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21518148)

  • 1. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
    Recht M; Pollmann H; Tagliaferri A; Musso R; Janco R; Neuman WR
    Haemophilia; 2011 May; 17(3):494-9. PubMed ID: 21518148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
    Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
    Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
    Uprichard J; Adamidou D; Goddard NJ; Mann HA; Yee TT
    Haemophilia; 2012 Jan; 18(1):46-9. PubMed ID: 21545378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
    Björkman S
    Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
    Poon MC; Lillicrap D; Hensman C; Card R; Scully MF
    Thromb Haemost; 2002 Mar; 87(3):431-5. PubMed ID: 11916075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M; Warrier I; Rajpurkar M; Lusher JM
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
    Alamelu J; Bevan D; Sorensen B; Rangarajan S
    J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
    Berntorp E; Keeling D; Makris M; Tagliaferri A; Male C; Mauser-Bunschoten EP; Musso R; Roca CA; Hassoun A; Kollmer C; Charnigo R; Baumann J; Rendo P
    Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
    Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of anaphylactic shock in haemophilia B patients with inhibitors.
    Warrier I; Lusher JM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.
    Polack B; Calvez T; Chambost H; Rothschild C; Goudemand J; Claeyssens S; Borel-Derlon A; Bardoulat I; Maurel F; Woronoff-Lemsi MC;
    Transfusion; 2015 Jul; 55(7):1787-97. PubMed ID: 25652955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV; Hogwood J; Gray E
    Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
    Quon DV; Logan L
    Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
    J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.